Tackling Inflammation with Novel Peptide Drugs

U.S. CDMO Capacity

More Than Capacity: What the Latest U.S. CDMO Expansion Wave Reveals About Specialized Manufacturing Demand

Pharma's Almanac

Peptides

Enabling the Commercialization of Peptide Therapeutics with Manufacturing Advances

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Peptide Production

Peptide Manufacturing Enters the Industrial Era

David Alvaro, Ph.D.

Pharma's Almanac

Peptides

The Resurgence of Peptide Drugs in the Age of Precision Medicine

David Alvaro, Ph.D.

Pharma's Almanac

Greener TIDES

Greener Pathways for Peptide and Oligonucleotide Manufacturing

David Alvaro, Ph.D.

Pharma's Almanac

Cell Therapy

Building a Better Cell Therapy CDMO

Kincell Bio

Biologics

HIPRA Biotech Services' End-to-End Biologics Offering

HIPRA Biotech Services

Biotech

Australia: Life Sciences' New Frontier

Mark W. Womack

BioCina

Sterile

Expanding Sterile Fill-Finish for the Next Era of Biologics

Afton Scientific

Cell Therapy

How Kincell Bio is Supporting Tomorrow's Cell Therapy Innovators

Mark Bamforth

Kincell Bio

Biomanufacturing

Organoids, ADCs, and More on the Horizon at Samsung Biologics

Kevin Sharp

Samsung Biologics

Biomanufacturing

Exploring Australia's Burgeoning Life Sciences Market with BioCina

Mark W. Womack

BioCina